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background
 
On the basis of a previous meta-analysis, the International Adjuvant Lung Cancer Trial
was designed to evaluate the effect of cisplatin-based adjuvant chemotherapy on survival
after complete resection of non–small-cell lung cancer.
 
methods
 
We randomly assigned patients either to three or four cycles of cisplatin-based chemo-
therapy or to observation. Before randomization, each center determined the patholog-
ical stages to include, its policy for chemotherapy (the dose of cisplatin and the drug to
be combined with cisplatin), and its postoperative radiotherapy policy. The main end
point was overall survival.
 
results
 
A total of 1867 patients underwent randomization; 36.5 percent had pathological stage
I disease, 24.2 percent stage II, and 39.3 percent stage III. The drug allocated with cisplat-
in was etoposide in 56.5 percent of patients, vinorelbine in 26.8 percent, vinblastine in
11.0 percent, and vindesine in 5.8 percent. Of the 932 patients assigned to chemother-
apy, 73.8 percent received at least 240 mg of cisplatin per square meter of body-surface
area. The median duration of follow-up was 56 months. Patients assigned to chemother-
apy had a significantly higher survival rate than those assigned to observation (44.5 per-
cent vs. 40.4 percent at five years [469 deaths vs. 504]; hazard ratio for death, 0.86; 95
percent confidence interval, 0.76 to 0.98; P<0.03). Patients assigned to chemotherapy
also had a significantly higher disease-free survival rate than those assigned to observa-
tion (39.4 percent vs. 34.3 percent at five years [518 events vs. 577]; hazard ratio, 0.83;
95 percent confidence interval, 0.74 to 0.94; P<0.003). There were no significant inter-
actions with prespecified factors. Seven patients (0.8 percent) died of chemotherapy-
induced toxic effects.
 
conclusions
 
Cisplatin-based adjuvant chemotherapy improves survival among patients with com-
pletely resected non–small-cell lung cancer.
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orldwide, lung cancer ac-
 
counts for the largest number of new
cases of cancer and of deaths from can-
cer annually.
 
1
 
 Complete surgical resection, when-
ever feasible, is generally recognized as the most
effective initial treatment for non–small-cell lung
cancer. Despite several randomized trials, adjuvant
treatment has not been shown to benefit patients
who have undergone complete resection, and pro-
longed adjuvant treatment with alkylating agents
 
2
 
or with radiotherapy
 
3
 
 in patients with early-stage
disease has even had deleterious effects on long-
term survival. A meta-analysis
 
2
 
 suggested that cis-
platin-based adjuvant chemotherapy could yield an
absolute overall survival advantage of 5 percent at
five years. Several cooperative groups launched pro-
spective, randomized trials to test this hypothesis.
The main objective of the International Adju-
vant Lung Cancer Trial (IALT) was to compare the
effect on overall survival of adjuvant chemotherapy
consisting of cisplatin plus a vinca alkaloid or eto-
poside with that of no adjuvant chemotherapy in pa-
tients with completely resected non–small-cell lung
cancer.
 
trial design and treatment options
 
Each participating center could determine the
pathological stages of disease to include, the dose of
cisplatin given per cycle, the drug that was combined
with cisplatin, and the postoperative radiotherapy
policy. Each center selected its options (Table 1) be-
fore the study began. Postoperative radiotherapy,
when delivered, was given after the completion of
chemotherapy in the chemotherapy group. This
open-choice design was chosen to facilitate accrual,
allow broad generalization of the results, and take
into account the uncertainty regarding the best
available chemotherapy regimen.
 
eligibility criteria
 
Eligible patients had pathologically documented
non–small-cell lung cancer of stage I, II, or III (ac-
cording to the 1986 classification of the American
Joint Committee on Cancer
 
4
 
) and had undergone a
complete surgical resection. Other inclusion criteria
were an age between 18 and 75 years and the ab-
sence of previous chemotherapy or radiotherapy,
contraindications to chemotherapy, and previous
cancer other than nonmelanoma skin cancer or car-
cinoma in situ of the cervix. Local ethics committees
approved the protocol according to the legal regula-
tions in each participating country. When the study
began in 1995, informed consent was obtained from
each patient according to the regulations of the par-
ticipating country; in 1999, all participants were re-
quired to give written informed consent.
 
randomization
 
Eligible patients were randomly assigned to the ad-
juvant-chemotherapy group or the control group by
fax within 60 days after surgery through a central-
ized randomization system at the Institut Gustave-
Roussy in Villejuif, France. Randomization was
stratified according to the center, type of surgery
(pneumonectomy vs. other surgical procedures),
and pathological stage (I vs. II vs. III) with the use of
a minimization procedure.
 
5
 
 Patients from Sweden
underwent randomization through the Uppsala On-
cologic Center with stratification according to the
same factors. In the chemotherapy group, the as-
signed treatment was to start within 60 days after
surgery and within 14 days after randomization.
 
follow-up
 
Six months after randomization, the data center col-
lected a one-page treatment form describing the
treatment administered and the occurrence of World
Health Organization (WHO) toxic effects of grade
4 or grade 5 (lethal)
 
6
 
 in each patient. Subsequently,
the same one-page follow-up form was required an-
nually. All patients had to be followed until death or
the cut-off date of the analysis.
 
site visits and trial monitoring
 
Site visits were performed at all centers that included
30 or more patients and at other, randomly selected
centers. A steering committee composed of investi-
gators from different countries met yearly to moni-
tor the progress of the trial. An independent data-
monitoring committee comprising two clinicians
and two statisticians examined the progress of the
study, adverse effects, and the interim analyses.
 
statistical analysis
 
The primary end point was overall survival after ran-
domization. Secondary end points were disease-free
survival, second primary cancers, and adverse ef-
fects. The events considered in disease-free survival
were locoregional or distant recurrences and death
without a recurrence. Median follow-up was esti-
mated with the use of the inverse Kaplan–Meier
method.
 
7
w
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The trial was designed to demonstrate an abso-
lute improvement in survival of 5 percent, from 50
percent to 55 percent, at five years with adjuvant
chemotherapy, on the basis of the hypothesis gen-
erated by the meta-analysis.
 
2
 
 A total of 3300 patients
was required to provide the study with 90 percent
power with a 5 percent type I one-sided error rate
(with the use of a log-rank test). The trial was refor-
mulated with a two-sided test on the recommenda-
tion by the data-monitoring committee, and this
change provided the study with a power of 83 per-
cent to detect a 5 percent difference in survival and
a power of 90 percent to detect a 5.6 percent differ-
ence with the same sample size. Interim analyses
were planned after 320 and 640 deaths. The data-
monitoring committee was to consider stopping the
trial if the results differed significantly between
groups (P<0.001).
 
8
 
All analyses were performed strictly according to
the intention-to-treat principle and included all ran-
domized patients, eligible or not. For the main
analysis of overall survival, we used a Cox model
 
9
 
 ad-
justed according to previously defined stratification
factors (center, stage of disease, and type of sur-
gery). For secondary analyses, we used Cox models
to study variations in treatment effects according to
major base-line characteristics (age, sex, perfor-
mance status, type of surgery, stage of disease,
pathological nodal [N] stage, and histologic find-
ings) and treatment options (the dose of cisplatin,
the drug that was combined with cisplatin, and the
radiotherapy policy). All reported P values are two-
sided. Data were entered and checked with the use
of PIGAS software
 
10
 
 and analyzed with the use of
SAS software, version 8.2.
 
accrual
 
Enrollment started in February 1995. Beginning in
1999, the rate of enrollment slowed, mainly because
of rising interest in the preoperative use of chemo-
therapy. Because of this decrease, the steering com-
mittee, whose members were unaware of the results
of any interim analyses, decided to discontinue re-
cruitment as of December 31, 2000, with the ap-
proval of the data-monitoring committee. A total of
1867 patients underwent randomization. They were
recruited by 148 centers in 33 countries. Fifty cen-
ters, each of which enrolled 10 or more patients, en-
rolled a total of 1468 patients. The cut-off date for
the analysis of follow-up data was September 1,
2002. The median follow-up was 56 months in each
group. The survival status of 1831 patients (98.1
percent) was known in 2002. The remaining 36 pa-
tients can be considered as lost to follow-up.
results
 
* The frequency of delivery was adapted according to the blood count.
† Postoperative radiotherapy consisted of 60 Gy or less, delivered to mediastinal lymph nodes, with conventional fraction-
 
ation of the dose. N denotes node in the TNM (tumor–node–metastasis) staging system.
 
Table 1. Treatment Options Offered to Each Participating Center.
Treatment Option Timing of Treatment
 
Cisplatin
80 mg/m
 
2
 
 for 4 cycles
100 mg/m
 
2
 
 for 3 cycles
100 mg/m
 
2
 
 for 4 cycles
120 mg/m
 
2
 
 for 3 cycles
Days 1, 22, 43, 64
Days 1, 29, 57
Days 1, 29, 57, 85
Days 1, 29, 71
Drug combined with cisplatin
Vindesine, 3 mg/m
 
2
 
 per day
Vinblastine, 4 mg/m
 
2
 
 per day
Vinorelbine, 30 mg/m
 
2
 
 per day
Etoposide, 100 mg/m
 
2
 
 per day
Weekly from days 1 to 29*
Then every 2 weeks after day 43 until last cisplatin administration
Weekly from days 1 to 29*
Then every 2 weeks after day 43 until last cisplatin administration
Weekly from day 1 to last cisplatin administration*
Days 1 to 3 with each cisplatin administration
Postoperative radiotherapy†
Never
Pathological stage N2 only
Pathological stages N1 and N2
After chemotherapy in the chemotherapy group, after randomization in the control 
group
After chemotherapy in the chemotherapy group, after randomization in the control 
group
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study population
 
Among the 1867 patients, 932 were randomly as-
signed to the chemotherapy group and 935 to the
control group. Table 2 shows the base-line charac-
teristics of the patients. Twenty-five patients were
found to be ineligible: 17 in the chemotherapy group
(10 underwent randomization between 61 and 122
days after surgery, 4 were older than 75 years of age,
1 had a previous lung cancer, 1 had a sarcomatoid
carcinoma, and 1 had a history of nephropathy)
and 8 in the control group (4 patients underwent
randomization between 61 and 122 days after sur-
gery, 1 had a previous lung cancer, 1 had a previous
bladder cancer, 1 had incomplete tumor resection,
and 1 had a lung metastasis from a urothelial carci-
noma).
 
therapy
 
Options
 
The chemotherapy options chosen are shown in Ta-
ble 3. A regimen combining 100 mg of cisplatin per
square meter of body-surface area for three or four
cycles with etoposide was selected for 49.3 percent
of the patients. Overall, postoperative radiotherapy
was planned for 30.6 percent of patients (1.9 per-
cent with pathological stage N0 disease, 33.7 per-
cent with pathological stage N1, and 64.3 percent
with pathological stage N2).
 
Compliance
 
In the chemotherapy group, 73.8 percent of patients
received at least 240 mg of cisplatin per square
meter and 7.8 percent never received chemotherapy,
mainly because of the patient’s or physician’s refus-
al. The chief reasons for incomplete treatment were
adverse effects (in 51.5 percent of patients), the pa-
tient’s or physician’s decision (24.3 percent), early
death (8.1 percent), or disease progression (5.1 per-
cent). The median delay between surgery and the
start of chemotherapy was 40 days, and the delay ex-
ceeded 60 days in 6.6 percent of the patients. In the
control group, 2.1 percent of the patients received
chemotherapy.
Among the 572 patients (284 in the chemother-
apy group and 288 in the control group) assigned
to receive adjuvant thoracic radiotherapy, only 70.4
percent of those in the chemotherapy group and
84.2 percent of those in the control group actually
received this treatment. This difference was mainly
due to a longer delay between randomization and
radiotherapy in the chemotherapy group; during
this period certain events (e.g., early death or disease
progression) prevented some patients from receiv-
ing radiotherapy. Among the 1295 patients who
were not assigned to receive radiotherapy, 2.3 per-
cent of those in the chemotherapy group actually
received radiotherapy, as did 2.6 percent of those in
the control group. The median total dose of post-
operative radiotherapy was 50 Gy.
 
Acute Toxic Effects of Chemotherapy
 
In the chemotherapy group, 851 patients received
chemotherapy. Seven patients (0.8 percent) died of
toxic effects of chemotherapy: bone marrow aplasia
 
* Because of rounding, percentages may not total 100. WHO denotes World 
Health Organization.
† Four patients were older than 75 years of age: two were 76 years old, and two 
were 77 years old.
‡ The 1986 classification of the American Joint Committee on Cancer was used 
 
to determine the tumor (T) and node (N) stage.
 
4
 
Table 2. Characteristics of the Patients.*
Characteristic
Chemotherapy Group
(N=932)
Control Group
(N=935)
 
Age — yr
Median
Range
59
27–77†
59
32–75
Sex — no. (%)
Male
Female
752 (80.7)
180 (19.3)
750 (80.2)
185 (19.8)
Pathological TNM stage — no. (%)‡
Stage I
T1N0
T2N0
Stage II
T1N1
T2N1
Stage III
T3N0
T3N1
T1N2
T2N2
T3N2
T4N0
T4N1
T4N2
96 (10.3)
237 (25.4)
40 (4.3)
190 (20.4)
84 (9.0)
38 (4.1)
33 (3.5)
143 (15.3)
60 (6.4)
6 (0.6)
3 (0.3)
2 (0.2)
87 (9.3)
261 (27.9)
40 (4.3)
182 (19.5)
73 (7.8)
37 (4.0)
24 (2.6)
160 (17.1)
54 (5.8)
6 (0.6)
8 (0.9)
3 (0.3)
Type of surgery — no. (%)
Pneumonectomy
Lobectomy
Segmentectomy
324 (34.8)
595 (63.8)
13 (1.4)
324 (34.6)
603 (64.5)
8 (0.9)
WHO performance status — no. (%)
0
1
2
505 (54.2)
355 (38.1)
72 (7.7)
499 (53.4)
372 (39.8)
64 (6.8)
Histologic type — no. (%)
Squamous-cell carcinoma
Adenocarcinoma
Large-cell carcinoma
Mixed
Other
428 (45.9)
386 (41.4)
60 (6.4)
40 (4.3)
18 (1.9)
444 (47.5)
368 (39.4)
62 (6.6)
41 (4.4)
20 (2.1)
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in five patients, renal failure in one, and hyponatre-
mia in one. Two of these patients had received a cis-
platin dose of 120 mg per square meter, four had re-
ceived a dose of 100 mg per square meter, and one
had received a dose of 80 mg per square meter. The
rate of lethal toxic effects was 2.4 percent after a cis-
platin dose of 120 mg per square meter, as com-
pared with 0.6 percent after a dose of 100 mg per
square meter or less (P=0.15). A total of 22.6 per-
cent of the patients had at least one episode of a
grade 4 toxic effect, mainly neutropenia (17.5 per-
cent), thrombocytopenia (2.6 percent), and vomit-
ing (3.3 percent). The rates of other grade 4 toxic
effects did not exceed 1.0 percent.
 
overall survival
 
Among the 1867 randomized patients, 973 died:
469 in the chemotherapy group and 504 in the con-
trol group. The survival rate was significantly higher
in the chemotherapy group (P<0.03) (Fig. 1A). The
hazard ratio for death was 0.86 (95 percent confi-
dence interval, 0.76 to 0.98) in the chemotherapy
group. The two-year survival rates were 70.3 percent
in the chemotherapy group and 66.7 percent in the
control group, and the five-year survival rates were
44.5 percent and 40.4 percent, respectively (Fig.
1A). Progression of disease caused the death of 361
patients in the chemotherapy group and of 405 pa-
tients in the control group. Hazard-ratio variations
were studied according to predefined factors, in-
cluding treatment options, demographic charac-
teristics (age and sex), and clinical characteristics
(stage of disease, type of surgery, histologic type,
and WHO performance status). All P values for the
interactions were 0.14 or higher (Fig. 2). The result
of the test for heterogeneity of the treatment effect
among center strata was not significant (P=0.11).
 
disease-free survival
 
There were 518 events (disease progression or
death) in the chemotherapy group and 577 in the
control group. The disease-free survival rate was sig-
nificantly higher in the chemotherapy group (P<
0.003) (Fig. 1B). The hazard ratio for death or recur-
rence was 0.83 (95 percent confidence interval, 0.74
to 0.94) in the chemotherapy group. The two-year
disease-free survival rates were 61.0 percent in the
chemotherapy group and 55.5 percent in the control
group, and the five-year disease-free survival rates
were 39.4 percent and 34.3 percent, respectively
(Fig. 1B). There were no significant interactions be-
tween treatment and the covariates, as defined for
overall survival (all P values were above 0.15).
This large trial showed that cisplatin-based che-
motherapy improves survival among patients who
have undergone complete resection of non–small-
cell lung cancer. The hypothesis we tested was based
on the results of a meta-analysis of chemotherapy
for non–small-cell lung cancer,
 
2
 
 which showed a
nonsignificant 5 percent absolute increase in the
five-year survival rate with the use of adjuvant cis-
platin-based chemotherapy (without postoperative
radiotherapy). Our study was launched just after the
publication of the meta-analysis.
 
2
 
 An open-choice
design was adopted. The optimal dose of cisplatin
per cycle was controversial, so we settled on a range
between 80 and 120 mg per square meter per cycle,
for a total dose of 300 to 400 mg per square meter.
The drugs that were combined with cisplatin were
those available in most countries at the time the
study was launched. In addition, when the study
was planned, there was uncertainty about the stages
discussion
 
Table 3. Distribution of Patients as Stratified According to the Chemotherapy Options Chosen before Randomization.
Dose of Cisplatin Drug Combined with Cisplatin
 
Vindesine Vinblastine Vinorelbine Etoposide Total
 
number of patients
 
80 mg/m
 
2
 
 of body-surface area for 4 cycles 4 105 124 94 327
100 mg/m
 
2
 
 for 3 cycles 103 43 185 484 815
100 mg/m
 
2
 
 for 4 cycles 0 57 48 436 541
120 mg/m
 
2
 
 for 3 cycles 1 0 143 40 184
Total 108 205 500 1054 1867
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of disease that were likely to benefit from adjuvant
chemotherapy and about the indications for post-
operative radiotherapy. Restricting the amount of
information collected at randomization and during
follow-up facilitated enrollment, as in previous
trials.
 
11,12
 
The absolute five-year benefit in overall survival
was 4.1 percent, a value that is concordant with the
estimation from the chemotherapy meta-analy-
sis.
 
2
 
 Survival according to the stage of disease in
our study was similar to that in the meta-analysis.
Our study also showed a benefit of chemotherapy
with respect to disease-free survival (an absolute
difference of 5.1 percent at five years). There were
no significant interactions between treatment effect
and the patients’ characteristics or the treatment op-
tions on overall or disease-free survival. One fourth
of the patients received postoperative radiothera-
py, with a moderate excess in the control group
(27.7 percent vs. 22.9 percent). Radiotherapy might
have increased the rate of death from causes other
than cancer in the control group, thereby artificial-
ly increasing the benefit of adjuvant chemotherapy.
However, this possibility appears to be highly un-
likely because the deleterious effect of adjuvant
radiotherapy in the Postoperative Radiotherapy
(PORT) meta-analysis
 
3
 
 was most apparent in pa-
tients with pathological stage N0 or N1 disease; pa-
tients with stage N0 or N1 who received radiother-
apy accounted for only 9.9 percent of the patients in
our study. There was, moreover, no significant inter-
action between the effect of chemotherapy and post-
operative radiotherapy (P=0.66).
The size of the absolute benefit derived from ad-
juvant treatment in our study is meaningful,
 
1,13
 
 giv-
en that worldwide, every year about 900,000 people
below the age of 75 years receive the diagnosis of
lung cancer.
 
1,13
 
 Approximately 80 percent of these
cancers are non–small-cell carcinomas, one third of
those are resectable, and 75 percent of those are can-
didates for adjuvant chemotherapy. Thus, approxi-
mately 180,000 cases would be eligible for treatment
annually. Our results indicate that roughly 7000
deaths from non–small-cell carcinoma would be
averted annually with the use of adjuvant cisplatin-
based chemotherapy.
Our study can be compared with three recent ran-
domized trials of adjuvant chemotherapy.
 
14-16
 
 The
Adjuvant Lung Project Italy–European Organization
for Research and Treatment of Cancer trial enrolled
1209 patients,
 
14
 
 of whom 1088 were included in
the analysis. The chemotherapy regimen combined
mitomycin, vindesine, and cisplatin (100 mg per
square meter) for three cycles. Forty-three percent
of the patients received postoperative radiotherapy.
The hazard ratio for death in the adjuvant-therapy
group, as compared with the control group, was
0.96 (95 percent confidence interval, 0.81 to 1.13).
It is noteworthy that in a randomized trial investigat-
ing preoperative chemotherapy,
 
17
 
 mitomycin-based
chemotherapy was also associated with an excess of
early deaths. The second trial evaluated the use of
uracil–tegafur as adjuvant chemotherapy in 979 pa-
tients with pathological stage T1N0 or T2N0 adeno-
carcinoma.
 
15
 
 A significant survival benefit was ob-
 
Figure 1. Overall Survival (Panel A) and Disease-free Survival (Panel B).
 
The hazard ratio for death in the chemotherapy group as compared with 
the control group was 0.86 (95 percent confidence interval, 0.76 to 0.98), 
and the hazard ratio for disease progression or death was 0.83 (95 percent 
confidence interval, 0.74 to 0.94).
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Figure 2. Hazard Ratios (with 95 Percent Confidence Intervals) for Death in Prespecified Subgroups of Patients 
in the Chemotherapy Group, as Compared with Patients in the Control Group.
 
WHO denotes World Health Organization.
0.0 0.5 1.0 1.5 2.0 2.5
0.46 0.26Age
<55 yr 141/314 163/316
55–64 yr 181/355 214/386
>64 yr 147/263 127/233
0.65 —Sex
Male 390/752 417/750
Female 79/180 87/185
0.210.14WHO performance status 
0 240/505 259/499
1 186/355 213/372
2 43/72 32/64
—0.98Type of surgery 
Pneumonectomy 182/324 193/324
Lobectomy or
segmentectomy
287/608 311/611
1 67/169 59/151
2 282/570 314/603
3 or 4 120/193 131/181
0 164/423 174/427
1 144/271 155/267
2 161/238 175/241
I 115/333 122/348
II 123/230 126/222
III 231/369 256/365
Squamous cell 205/428 223/444
Adenocarcinoma 199/386 208/368
Other 65/118 73/123
80 mg/m2 85/163 93/164
100 mg/m2 334/679 360/677
120 mg/m2 50/90 51/94
Vindesine 26/52 26/56
Vinblastine 62/103 70/102
Vinorelbine 113/248 128/252
Etoposide 268/529 280/525
No 287/648 303/647
Yes 182/284 201/288
Total 469/932 504/935
Covariate
Chemotherapy
Group
Control
Group
P Value for
Interaction
P Value
for Trend
No. of deaths/No. of patients
Hazard Ratio
Chemotherapy
Better
Control Better
Tumor stage 0.57 0.32
Nodal status 0.80 0.56
Stage 0.41 0.21
—Histologic type 0.77
Dose of cisplatin per cycle 0.45 0.63
—Drug combined with cisplatin 0.77
—Planned radiotherapy 0.66
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served with adjuvant chemotherapy (P=0.04), but
the benefit appeared to be limited to the subgroup
with T2N0 disease. The results of these two trials
and our trial are in the same range. A North Amer-
ican Intergroup trial
 
16
 
 enrolled 488 patients and
compared postoperative radiotherapy alone with
radiotherapy plus concurrent treatment with eto-
poside and cisplatin. No significant difference was
observed in overall survival (hazard ratio for death
in the chemotherapy group, 1.08; 95 percent con-
fidence interval, 0.85 to 1.35). The concomitant use
of chemotherapy and radiotherapy may explain this
negative result.
Other studies evaluating cisplatin-based chemo-
therapy have recently been completed. A joint analy-
sis of the largest recent trials of adjuvant cisplatin-
based chemotherapy (Lung Adjuvant Cisplatin
Evaluation [LACE]) is under way. This analysis will
include more than 4000 patients and will allow po-
tential predictive factors for treatment effects to be
investigated with more statistical power than in our
study. The large number of patients evaluated in
postoperative-chemotherapy trials contrasts with
the total of less than 600 patients included in the re-
ported randomized studies of preoperative chemo-
therapy; this approach remains investigational in
early non–small-cell lung cancer.
 
18
 
 Moreover, the
use of new cytotoxic drugs should be evaluated in
future trials.
The benefit of adjuvant treatment has been dem-
onstrated in several other cancers in adults. Postop-
erative chemotherapy in patients with early breast
cancer yields an absolute overall survival benefit of
3.2 percent at 5 years and 6.3 percent at 10 years.
 
19
 
Adjuvant tamoxifen in the same setting yields an
overall benefit of 3.6 percent at 5 years and 6.2 per-
cent at 10 years.
 
19
 
 In patients with early ovarian can-
cer,
 
20
 
 platinum-based chemotherapy affords a sur-
vival benefit of 8 percent at five years. In patients
with colon cancer,
 
21
 
 fluorouracil and folinic acid af-
ford a survival benefit of 5 percent at three years for
Dukes’ class B or C tumors. Both thoracic radiother-
apy
 
22
 
 and prophylactic brain irradiation
 
23
 
 result in
a survival benefit of 5.4 percent at three years in pa-
tients with small-cell lung cancer.
A large proportion of patients with cancer receive
adjuvant treatment without any benefit, and some
have only adverse effects. The proportion of deaths
that are due to toxic effects of treatment is generally
below 1.0 percent (0.8 percent in our study). Even if
this proportion is low, the importance of treatment-
induced toxicity should be considered in the indi-
cations for treatment and in the discussion of treat-
ment with patients. We did not identify a group of
patients who failed to benefit from adjuvant cisplat-
in-based chemotherapy. However, it might be pos-
sible to single out such a group in a larger popula-
tion of patients, such as that included in the LACE
project. In addition, the IALT study includes a pro-
gram aimed at studying tissue specimens from
about 1000 patients in order to identify potential
markers that could better define candidates for che-
motherapy.
In conclusion, our results strongly support the
use of three or four cycles of cisplatin-based che-
motherapy after complete surgical resection in pa-
tients with non–small-cell lung cancer. The benefit
observed is in the same range as the improvement
obtained with adjuvant chemotherapy in patients
with other cancers, such as breast cancer, colon can-
cer, and ovarian cancer.
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